Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (61)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Al-Nakib, W.
Right arrow Articles by Tyrrell, D.A.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Nakib, W.
Right arrow Articles by Tyrrell, D.A.J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1987) 20, 893-901
© 1987 The British Society for Antimicrobial Chemotherapy


research-article

Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges

W. Al-Nakiba,, P.G. Higginsa, I. Barrowa, G. Batstoneb and D.A.J. Tyrrella

aMRC Common Cold Unit, Harvard Hospital Salisbury, Wiltshire, UK bSalisbury General Infirmary Wiltshire, U.K.

accepted 21 July 1987


Correspondence to: W. Al-Nakib, MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wiltshire SP2 8BW, U.K.

Following a tolerance study, double-blind placebo controlled trials were conducted to determine the prophylactic effect of zinc gluconate lozenges on rhinovirus challenge and, in a third study, their therapeutic efficacy when given at the start of colds caused by virus inoculation was tested.

In the prophylaxis study a total of 57 volunteers received lozenges of either zinc gluconate (23 mg) (29 volunteers) or matched placebo (28 volunteers) every 2 h while awake during a period of four and a half days. They were challenged with 102 tissue culture infecting dose (TCID50) of human rhinovirus 2 (HRV-2) on the second day of medication, and were monitored daily for symptoms and signs of colds and laboratory evidence of infection. Zinc reduced the total mean clinical score from 8.2 in the placebo group to 5.7 and the reduction of the mean clinical score was statistically significant on the second day after virus challenge.

In the therapeutic study 69 volunteers were inoculated with 102 TCID50 of HRV-2 and those who developed cold symptoms were randomly allocated to receive either zinc gluconate lozenges (six volunteers) or matched placebo lozenges (six volunteers) every two hours they were awake for six days. Treatment of colds with zinc reduced the mean daily clinical score and this was statistically significant on the fourth and fifth day of medication. Similarly, medication also reduced the mean daily nasal secretion weight and total tissue count and these reductions were statistically significant on days two and six for nasal secretion weights and days four to six of medication for tissue counts when compared with placebo. There were also statistically significant reductions in the mean total nasal secretion weights and total tissue counts. Zinc, however, had no significant effect on the rate or amount of virus excreted by volunteers.

We conclude that zinc gluconate lozenges are reasonably well tolerated and that they have a significant effect on the signs and symptoms of colds caused by rhinoviruses, although the mechanism of action remains obscure.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ChestHome page
D. C. Bolser
Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines
Chest, January 1, 2006; 129(1_suppl): 238S - 249S.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
A. S. Prasad, J. T. Fitzgerald, B. Bao, F. W.J. Beck, and P. H. Chandrasekar
Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate: A Randomized, Double-Blind, Placebo-Controlled Trial
Ann Intern Med, August 15, 2000; 133(4): 245 - 252.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
L. Rink and H. Kirchner
Zinc-Altered Immune Function and Cytokine Production
J. Nutr., May 1, 2000; 130(5): 1407S - 1411.
[Abstract] [Full Text]


Home page
J. Nutr.Home page
M. K. Baum, G. Shor-Posner, and A. Campa
Zinc Status in Human Immunodeficiency Virus Infection
J. Nutr., May 1, 2000; 130(5): 1421S - 1423.
[Abstract] [Full Text]


Home page
J. Nutr.Home page
J. L. Jackson, E. Lesho, and C. Peterson
Zinc and the Common Cold: A Meta-Analysis Revisited
J. Nutr., May 1, 2000; 130(5): 1512S - 1515.
[Abstract] [Full Text]


Home page
PediatricsHome page
S. Sazawal, R. E. Black, S. Jalla, S. Mazumdar, A. Sinha, and M. K. Bhan
Zinc Supplementation Reduces the Incidence of Acute Lower Respiratory Infections in Infants and Preschool Children: A Double-blind, Controlled Trial
Pediatrics, July 1, 1998; 102(1): 1 - 5.
[Abstract] [Full Text]


Home page
JAMAHome page
M. L. Macknin, M. Piedmonte, C. Calendine, J. Janosky, and E. Wald
Zinc Gluconate Lozenges for Treating the Common Cold in Children: A Randomized Controlled Trial
JAMA, June 24, 1998; 279(24): 1962 - 1967.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. L. Jackson, C. Peterson, and E. Lesho
A Meta-analysis of Zinc Salts Lozenges and the Common Cold
Arch Intern Med, November 10, 1997; 157(20): 2373 - 2376.
[Abstract] [PDF]


Home page
Arch. Dis. Child.Home page
S K Roy, A M Tomkins, S M Akramuzzaman, R H Behrens, R Haider, D Mahalanabis, and G Fuchs
Randomised controlled trial of zinc supplementation in malnourished Bangladeshi children with acute diarrhoea
Arch. Dis. Child., September 1, 1997; 77(3): 196 - 200.
[Abstract] [Full Text]


Home page
J PsychopharmacolHome page
A.P. Smith, D.A.J. Tyrrell, W. Al-Nakib, I. Barrow, P. Higgins, and R. Wenham
Effects of zinc gluconate and nedocromil sodium on performance deficits produced by the common cold
J Psychopharmacol, January 1, 1991; 5(3): 251 - 254.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.